Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mLAG-3Ig
- Development stage
- Preclinical
- Lead developer
- Merck KGaA
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Injection
01
Overview
mLAG-3Ig is a recombinant fusion protein consisting of the extracellular domain of murine Lymphocyte Activation Gene-3 (LAG-3) fused to the Fc region of a murine IgG2a antibody. Developed by Ares Advanced Technology (a subsidiary of Serono, now part of Merck KGaA), it serves as a potent vaccine adjuvant. The protein functions by binding with high affinity to MHC class II molecules on professional antigen-presenting cells (APCs), such as dendritic cells. This engagement triggers APC activation and maturation, subsequently enhancing both humoral and cellular immune responses, specifically promoting Th1-type cytokine production and CD8+ T cell expansion. It has been primarily utilized in preclinical research to improve the immunogenicity of subunit vaccines against cancer and infectious diseases.
- Other names
- murine LAG-3Igmurine LAG-3-IgmLAG-3-IgmLAG3-IgmLAG 3-Ig
02
Targets
MHC II (Major histocompatibility complex class II receptor)
Beyond the preview
Go deeper on mLAG-3Ig.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mLAG-3Ig.